Hypocalcemia News and Research

RSS

Investigational drug restores calcium levels in rare genetic disorder

An investigational drug, encaleret, restored calcium levels in people with autosomal dominant hypocalcemia type 1 (ADH1), a rare genetic disorder marked by an imbalance of calcium in the blood and urine, as well as abnormally low levels of parathyroid hormone, which regulates blood calcium levels.

13 Oct 2023

Scientists develop nanoantidote to reduce acidosis in critically ill COVID-19 patients

A group of scientists from China has recently developed an antacid nanoantidote that can effectively ameliorate blood acidosis induced by SARS-CoV-2 infection.

11 Aug 2022

Examining hypomagnesemia in critically ill patients with Acute Kidney Injury (AKI)

In this interview, News-Medical talks to Dr. Francesca Di Mario, about hypomagnesemia in critically ill patients suffering from acute kidney injuries and discusses how Nova Biomedical instruments are utilized in her work.

From Nova Biomedical 6 Apr 2022

Exploring the potential utility of calcium channel inhibitors in SARS-CoV-2 infection

In a new study, researchers discuss the role of calcium signaling pathways as targets of inhibition in potential new antiviral therapeutic pathways for SARS-CoV-2.

20 Jan 2022

Study confirms that human endocrine system is strongly involved in SARS-Cov-2 infection

The endocrine system is strongly involved in SARS-Cov-2 infection - so much so that evidence of an "endocrine phenotype" of COVID-19 has emerged, according to a statement by the European Society of Endocrinology (ESE) published in the journal Endocrine in April 2021.

20 May 2021

Low potassium levels in COVID-19 disease

Now a new study by an Italian team of researchers published in June 2020 on the preprint server medRxiv reports that potassium levels are often low in COVID-19 disease, mostly due to the urinary loss of potassium.

17 Jun 2020

Researchers discover signaling protein that may protect parathyroid glands from hyperactivity

Overactive parathyroid glands,which control the body's blood calcium levels, can lead to kidney stones, neuropsychiatric disorders and bone abnormalities, particularly among elderly women.

29 May 2019

Pediatric patients undergoing thyroid surgery have better outcomes at high-volume centers

New research recently published in the Journal of Pediatric Surgery found that post-operative success rates of pediatric thyroid patients, particularly children who require a thyroidectomy, correlate with the institution's patient volume.

4 Apr 2019

FDA authorizes two devices that provide real-time location of parathyroid tissue during surgery

Today, the U.S. Food and Drug Administration permitted marketing of two devices that provide real-time location of parathyroid tissue during surgical procedures such as thyroidectomy (surgery to remove all or part of the thyroid) and parathyroidectomy (surgery to remove one or more parathyroid glands).

2 Nov 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Endocrine Society announces winners of prestigious 2019 Laureate Awards

The Endocrine Society today announced it has chosen 13 leading endocrinologists as winners of its prestigious 2019 Laureate Awards, the top honors in the field.

6 Sep 2018

FDA accepts Bristol-Myers Squibb’s application for Sprycel for treating pediatric leukemia

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

30 Aug 2018

Study points to dangers of feeding non-dairy drink to infants

A brief report published in Acta Paediatrica points to the dangers of replacing breast milk or infant formula with a non-dairy drink before one year of age.

20 Jun 2018

Vitamin D supplementation during pregnancy could protect against childhood obesity

Every parent wants to give their child the best start in life, but what if that consideration needed to happen before the baby was even born?

From BetterYou Ltd 20 Feb 2018

Large clinical study reveals the performance of Natera's Panorama® non-invasive prenatal test

Natera, Inc. a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the publication of a large clinical experience study evaluating the performance of the company's Panorama® non-invasive prenatal test (NIPT).

From Natera 31 Jul 2017

Thyroid cancer surgery complications higher than previously thought, study suggests

As thyroid cancer rates rise, more people are having surgery to remove all or part of their thyroid. A new study suggests complications from these procedures are more common than previously believed.

16 May 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.

3 Apr 2017

Study provides new insights into molecular basis of CaSR-related human diseases

A study led by researchers at Georgia State University provides new insights into the molecular basis of human diseases resulting from mutations in the calcium-sensing receptor (CaSR), a protein found in cell membranes.

1 Jun 2016

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016